Company news
Anteris Technologies Global Corp. (NASDAQ:AVR) news
Anteris Technologies Global Corp. news releases on 6ix. Latest, Aug 31, 2026: Anteris to Present at September Healthcare Investor Conferences
Press releases & updates
Anteris to Present at September Healthcare Investor Conferences
August 31, 2026
Anteris Technologies Announces Results for the Second Quarter of 2026
August 11, 2026
Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance
June 8, 2026
Anteris Appoints Susan Knight and Stephen Denaro to its Board of Directors
May 13, 2026
Anteris Announces Results for the First Quarter of 2026
May 12, 2026
Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial
May 5, 2026
Anteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM Trial
April 28, 2026
Anteris Reports 2025 Financial Results and Provides Corporate Update
February 25, 2026
Anteris to Present at Healthcare Investor Conferences TD Cowen and Barclays
February 23, 2026
Anteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital Raises
January 22, 2026
Anteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common Stock
January 22, 2026
Anteris Technologies Global Corp. Announces Pricing of $200 Million Public Offering
January 20, 2026
Anteris Technologies Global Corp. Announces Proposed $200 Million Public Offering of Common Stock and Strategic Investment from Medtronic
January 20, 2026
Anteris Technologies Presents Data from 100 DurAVR® THV Patients at PCR London Valves
November 17, 2025
Anteris Announces Results for the Third Quarter of 2025
November 12, 2025
FDA Approves Anteris’s DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)
November 3, 2025
Anteris DurAVR® THV Demonstrates Favorable Hemodynamics in Small Annuli Patients with no Valve Related Mortality at One Year
October 28, 2025
Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)
October 27, 2025
Anteris Technologies Announces One-Year Clinical Outcomes for DurAVR® THV to be Presented at TCT® 2025
October 27, 2025
Anteris Receives First European Regulatory Clearance to Commence DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)
October 15, 2025
Anteris Technologies Global Corp. Announces Adjournment of Special Meeting of Stockholders
September 19, 2025
Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders
September 11, 2025
Anteris Announces Results for the Second Quarter of 2025
August 11, 2025
Anteris Appoints David Roberts and Gregory Moss to its Board of Directors
June 9, 2025
Anteris Announces Results for the First Quarter of 2025
May 13, 2025
Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR® THV
March 31, 2025
Anteris Reports One-Year Patient Outcomes for DurAVR® THV
March 21, 2025
Anteris Reports 2024 Financial Results and Provides Corporate Update
March 11, 2025
Anteris to Present at Healthcare Investor Conferences - TD Cowen and Barclays
February 28, 2025
Anteris Technologies Global Corp. Announces Closing of $88.8 Million U.S. Initial Public Offering
December 15, 2024